Logo HTID Icone
Register Now

0

Days in Paris

0

International actors in HealthTech Innovation

0

Conferences and expert panel discussions on new trends in research & development and growth improvement

Our ambition

By renewing the HTID® (HealthTech Innovation Days) an event dedicated to Biotech, Medtech and Digital Health companies on October 5 and 6 2020, France Biotech confirms its desire to promote access for all patients to cutting-edge HealthTech technologies.
In June 2019, the HTID® event brought together more than 500 innovation experts in the health and life sciences fields and promoted more than 900 fruitful meetings between the players present, startups and funds.
In October 2020, it is the interest of the patient who will be at the heart of France biotech's aspirations, proving that access to innovative care for all, depends on partnerships between actors in health and finance, in Europe and elsewhere.
Maryvonne Hiance

President of HTID®

Europe is a land of innovation in health with many start-up and SME’s looking for financing to make their innovations available to patients and to meet the medical challenges of tomorrow. The objective of the HTID® is to become a reference place for exchanges between European HealthTech companies, international investors and pharmaceutical groups.
Franck Mouthon

President of France Biotech

Thanks to the innovations it develops for the benefit of patients, the HealthTech industry constitutes indeed a major societal issue for health. To ultimately reach patients, these developments are characterized by large funding needs and long durations.
Maryvonne Hiance

Présidente du HTID®

L’Europe est une terre d’innovation dans le domaine de la santé avec de nombreuses start-up et PME à la recherche de financements pour rendre leurs innovations accessibles aux patients et relever les défis médicaux de demain. L'objectif du HTID® est de devenir un lieu de référence pour les échanges entre les sociétés européennes HealthTech, les investisseurs internationaux et les groupes pharmaceutiques
Franck Mouthon

Président de France Biotech

La filière de la HealthTech, grâce aux innovations qu’elle développe au service des patients, constitue en effet un enjeu sociétal majeur pour la santé. Pour parvenir in fine jusqu’aux patients, ces développements se caractérisent par des besoins et des durées de financements importants.

What will you attend to?

Private meetings

To set up partnerships between European innovative companies and their growth supporters

Conferences & thematic panels

On specific topics supervised by well-known international scientific Key Opinion Leaders

Networking events

To gather the ecosystem

Be part of the European investment hub supporting European HealthTech companies development. Accelerate innovation by setting a privilege place between C-level executives from the most European innovative companies in HealthTech, worldwide investors, pharmaceutical companies, KOLs, experts and institutional representatives.
France is home to the largest number of life sciences start-ups in Europe. This fast-moving industry is facing disruptive innovations, which generate myriad complex legal issues, and we are glad as an international law firm to work alongside France Biotech to support businesses in the sector.
Alain Decombe Managing partner of Dechert's Paris office
It was great to attend and support HTID’s first edition. As the only American pharma company partner, this event was the opportunity for us to formalize our desire to invest in innovation in France and increase our synergies with many start-ups. (...) France is definitely a center of excellence in e-health, artificial intelligence and big data but also in biotech start-ups. We hope to be there next year with possible new partners and wish to be even more involved in the French innovation ecosystem.
Corinne Blanchier-Poisson Chairman of Amgen France
We are delighted to have participated to this 1st edition of the HTID. As a Belgian company, we can only applaud the support given by the French government to the European health ecosystem. In addition to bringing together the best companies in the sector and specialized investors, this event brings high visibility on a sector creating direct and indirect qualified jobs. Gathering all actors in this value chain can only be virtuous, allowing academic research to find an industrial outlet.
Filippo Petti CEO of Celyad

Targeted European Innovative Companies' Criteria

Open to private and listed companies

Biotech

At least on-going Phase 1, financement available for Phase 2

Medtech

CE or FDA filed (PMA, DeNovo, 510k, pre-subs) product

Innovative Med activities

Innovative services and functionalities under test by HealthTech partners

Digital Health

Services or functionalities in development with at least 1 fund raising

Want to work together?

Check out our partnership offers and join us on this must-attend HealthTech innovation event.
Become a part of the movement to foster stronger collaborations and partnerships within Europe to improve patient lives in the EU and beyond!

Partnership offers

Contact

Any question about the event ?
Please feel free to complete this form and we will come back to you.